@ERAkidney 💬 Editorial: In advanced #CKD, low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding risk. The TRACK trial highlights the necessity of disease-specific evidence before adopting preventative therapies.
#ERA26@ERAkidney
https://t.co/atyQ8vAbs6
Among adults with advanced chronic #kidney#disease (#CKD) stage 4 or 5 or on #dialysis, low-dose rivaroxaban did not lower #cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group.
#ERA26@ERAkidney
https://t.co/vGdedL3xzq